ABOUT US

Meet Prescient

At Prescient, science is at the core of everything we do.

We are a product and portfolio strategy partner that specializes in turning the science of molecules into optimal patient outcomes and client value.

At Prescient, doing things the right way is at the core of our culture.

The principles underpinning our corporate governance are set out in our Global Code of Conduct (“Global Code”), which provides a basic understanding of the standards of ethical conduct that Prescient requires around the world.

A little about us...

Founded in 2007, Prescient is a partner with global reach and specialized capabilities, with six offices across three continents. We work with 22 of the top 25 biopharmaceutical companies, the fastest-growing mid-caps and cutting-edge emerging biotechs, including some of the biggest and most innovative brands.

More than 80% of our employees hold advanced degrees and deliver impressive depth of therapeutic, clinical and commercial expertise, a wealth of relevant experience and knowledge of best practice and common pitfalls.

Meet Our Leadership

AllSenior LeadershipAdvisory LeadershipIntelligence & Insight LeadershipBusiness Operations Leadership
Chief Executive Officer

Jamie Denison-Pender

President, Intelligence & Insight

Dr. Rakesh Verma

President, North America

Dr. Paul Harney

President, India

Swati Kkatyal

Chief Operating Officer

Nick Denison-Pender

Chief Human Resources Officer

Victoria Muir

President, Advisory

Dr. Debasish Talukdar

Chief Financial Officer

Andrew McMeeking

Chairman

Dr. Nick Edwards

Bridgepoint Investor

Alan Payne

Bridgepoint Investor

Steve Bonnard

Baird Capital Investor

Andrew Ferguson

Baird Capital Investor

Michael Holgate

Vice President

Kevin Baruzzi

Vice President

Harminder Bhatia

Associate Vice President

Courtney Carlson

Vice President

Ben Doran

Senior Vice President

Dr. Mark Little

Vice President

Dr. Aviral Maheshwari

Vice President, Head of Software Development

Tarun Ojha

Vice President

Jeanne Penn

Vice President

Dr. Elisavet Primpidou

Vice President

Dr. Luke Solon

Vice President

Dr. Anthony Starling

Director

Amrit Bawa

Director

Katy Chun

Director

Peter Donachie

Director

Paula Palacios Fernández

Director

Anamika Gera

Director

Easha Ghildyal

Director

Gordon Gochenauer

Director

Nadia Gonzalez

Director

Dr. Anuj Gupta

Senior Director

Jatin Gupta

Director

Dr. Priya Kar

Associate Director

Dr. Haroon Khan

Director

Emma Leung

Director

Rob Littlefield

Director

Dr. Cameron Mackenzie

Global Head of Marketing

Christina Maffei

Director

Matt Majer

Senior Director

Dr. Kallal Pramanik

Director

Dr. Emmanuel Reyes-Cortes

Senior Director

Dr. Ashima Sharma

Senior Director

Sugandh Sharna

Director

Dr. Reena Telang

Director

Dr. Mladen Tomich

Senior Director

Dr. Nick Turner

Chief Executive Officer

Jamie Denison-Pender

Jamie is our CEO and a career consultant, having spent more than 20 years growing and managing pharmaceutical-focused insight and advisory firms. In 2007, he became managing director of a global competitive strategy firm and led the company’s transition from an industry generalist to a biopharmaceutical specialist. He rebranded the company to Prescient in 2010, led a management buyout in 2014 and the investment by Baird Capital in 2017. Jamie remains actively involved with our clients, mainly focusing on brand planning, mature brand strategies and strategy workshops.

President, Intelligence & Insight

Dr. Rakesh Verma

Rakesh is the President of our Intelligence & Insight business. After earning a degree in Veterinary Medicine, he completed his Master’s in immunology and PhD in immunology/oncology at Imperial College, School of Medicine, London. He was then recruited by oncology biotech firm Antisoma, which specialized in the development of antibodies based therapeutics for oncology. After working for more than a decade in oncology drug development, he joined Prescient in 2007. His renowned expertise in the development and commercialization of biologics makes him an extremely valuable asset to our oncology, immunology and biosimilar clients.

President, North America

Dr. Paul Harney

Paul oversees our business activities in North America. Since completing his PhD in chemistry at Stony Brook University, he has spent more than 20 years providing guidance and support to the healthcare industry. He has held leadership roles at various consulting firms, including Deloitte and Quintiles, that engage with biopharmaceutical and medical technology companies in nearly all functional areas, including sales, marketing, medical affairs, business development and supply chain. Paul’s focus at Prescient is helping our clients achieve and sustain peak commercialization targets across a wide range of therapy areas.

President, India

Swati Kkatyal

Swati is President of our sizable India-based business operations. She has an MSc in biotechnology and pharmacology, and an MBA from the University of Sheffield. After joining us in London in 2008, she moved to India in 2010 to set up the New Delhi office, which she has built into a critical part of our business. She has also been responsible for setting up the software development team and the analytics center for Prescient in India. Swati has extensive experience in consulting biopharma companies on new and mature brand planning strategies. She has directed engagements across multiple therapeutic areas and geographies, with a focus on the APAC region.

Chief Operating Officer

Nick Denison-Pender

Nick, our COO, joined Prescient in 2010. After studying engineering, he held various positions focused on business improvement, mainly in the construction industry. He has worked in many parts of the world, establishing and embedding businesses into local markets. At Prescient, he holds overall responsibility for our operations and infrastructure and has been instrumental in setting up the departments, processes and procedures required to support a growing business.

Chief Human Resources Officer

Victoria Muir

Victoria is a Vice President and our Chief Human Resources Officer. She has a Bachelor’s degree (Hons) in economics from Nottingham Trent University, as well as several accounting and human resources certifications. Victoria spent more than 20 years in senior leadership positions at KPMG across Europe and Asia, where she developed extensive experience and a proven ability to implement change in complex and cross-cultural environments. At Prescient, her role involves working with senior stakeholders to effectively prioritize and execute the people activities needed to achieve defined strategic objectives.

President, Advisory

Dr. Debasish Talukdar

Debasish is the President of our Advisory business. A physician by training, Debasish is a seasoned strategy advisor to biopharma leadership. After a brief stint early in his career at P&G, Debasish spent ten years at Bain & Company, where he was a leader in the healthcare practice. Debasish has extensive international experience across the US, EU and APAC markets advising biopharma leaders on value creation through corporate, business unit, disease area and product-focused strategies.

Chief Financial Officer

Andrew McMeeking

Andrew joined our team in 2012 after holding finance director positions in marketing services companies such as Publicis and Gyro. He is a qualified chartered accountant and holds an honors degree in accountancy from Dundee University. He manages Prescient’s finances and is the company secretary. He was heavily involved in setting up the shared resources service center in the UK and arranging Prescient’s de-merger/MBO in 2014.

Chairman

Dr. Nick Edwards

Nick serves as the Chairman of Prescient’s Board of Directors. He holds a degree in physiological sciences from The Queen’s College, University of Oxford, and completed his training in clinical medicine (BM, BCh) at Green College (now Green Templeton College), University of Oxford. Nick practiced in the areas of cardiology and general surgery before joining Andersen Consulting (now known as Accenture), eventually becoming the global leader of Accenture’s pharmaceutical R&D business during his 18-year tenure. In 2005, he founded Kinapse to provide consulting and outsourcing services to the pharmaceutical industry. Nick served as Kinapse’s Chairman until the company was sold to HgCapital in early 2016.

Bridgepoint Investor

Alan Payne

Alan is a founder Partner of Bridgepoint Development Capital. He sits on the BDC Board, Operating Committee and is a member of its Investment Advisory Committee. He joined Bridgepoint in 1996. Alan is currently a board member of portfolio companies Matrix and HKA. He has led a broad range of transactions including public to private and serial international buy and build investments. Previous transactions include Quotient Clinical, Phlexglobal, LOC Group, BigHand, The Energy Solutions Group, Pulsant and Safestore PLC. Prior to joining Bridgepoint he worked for Deloitte (formerly Arthur Andersen) in their corporate finance team. Alan has a degree in Finance from Birmingham University and is a Chartered Accountant.

Bridgepoint Investor

Steve Bonnard

Stephen is a Partner within Bridgepoint Development Capital and leads BDC’s Healthcare and Life Science practice. He joined the team in 2007. He has worked on a number of transactions, spanning a range of sectors, including investments in HKA, The Dining Club Group, Quotient Clinical, Phlexglobal, MVF, Inspired Thinking Group, Solhaga, Memnon Networks and Shimtech Industries. Prior to Bridgepoint Stephen worked at Deloitte within its M&A division where he advised on mid-market buyouts, principally in the Healthcare sector. Stephen qualified as a Chartered Accountant and holds the Chartered Financial Analyst designation. He also holds a postgraduate degree in Accounting and Finance from the University of Natal, South Africa.

Baird Capital Investor

Andrew Ferguson

Andrew, one of our non-executive board members, has close to 25 years’ experience in the private equity industry. He started his professional career at Price Waterhouse in 1986, where he qualified as a chartered accountant before moving into a corporate finance role. He joined North of England Ventures in 1993 to manage a regional investment fund before moving to Granville, subsequently Baird Capital Partners, in 1996. At Baird, he is responsible for investment activities in the UK with a particular focus on the business services and healthcare sectors and has held directorships in a large range of companies across these sectors.

Baird Capital Investor

Michael Holgate

Michael sits on our board of directors. He holds Bachelor’s and Master’s degrees in chemistry from the University of Bristol, where he graduated with First Class Honours. Michael began his career as a chemist working at GlaxoSmithKline and Synairgen. He then joined PricewaterhouseCoopers in its Transaction Services Team before spending time in Investment Banking at Spectrum Corporate Finance. Michael joined Baird Capital in 2014 and has a particular focus on technology and service-based businesses. During his time at Baird, Michael has spent time working in both London and Chicago. Michael is a chartered accountant.

Vice President

Kevin Baruzzi

Kevin is a Vice President in our Advisory business and leads our Boston office. He earned his BSc in neuroscience and economics from Brown University and has since worked in life sciences and biopharma strategy consulting, spending the better part of a decade at ClearView Healthcare Partners prior to joining Prescient. Kevin has led multiple engagements across a range of therapeutic areas and geographies. He is experienced in target product profile development and evaluation, therapeutic area and indication prioritization, competitive strategy, opportunity assessment, due diligence, life cycle management and clinical development strategy. At Prescient, Kevin ensures client satisfaction through high-quality, tailored and targeted recommendations.

Vice President

Harminder Bhatia

Harminder is a Vice President and has been delivering high-impact projects to our clients since 2010. He has an MS degree in chemistry from Virginia Commonwealth University and a BPharm degree from Panjab University. He is also a registered pharmacist. Before joining Prescient, he worked in pharmaceutical product manufacturing, regulatory and corporate departments. At Prescient, Harminder has focused on analyzing competitors and market scenarios for biosimilar, generic and novel products. He has also worked at building client relationships and motivating teams to better serve client needs.

Associate Vice President

Courtney Carlson

Courtney, our Associate Vice President of Operations, joined Prescient in 2012. After earning a master’s degree in Spanish translation, she pursued a job opportunity in Bogotá, Colombia, where she translated medical, legal and technical texts and designed an assessment program to monitor the quality of her fellow translators’ work. Courtney is responsible for various operational aspects of our business, including quality control, compliance and US resourcing.

Vice President

Ben Doran

Ben is a Vice President and supports both our East and West Coast clients in the US. He holds a BSc in biomedical sciences and an MSc in biomedical engineering, and gained eight years’ experience in biotech prior to joining Prescient in 2010. Ben has held progressively more senior roles at Prescient, which has given him a deep understanding of what is needed to build and motivate teams that deliver results with a high degree of client satisfaction. Ben has also been closely involved in managing projects across multiple therapeutic areas, including oncology, immunology and biosimilars.

Senior Vice President

Dr. Mark Little

Mark is the Senior Vice President of our North American business. After completing a PhD in biochemistry at The Ohio State University, he spent more than 10 years running GSK’s competitive strategy function and 10 years as a key member of Covance’s executive strategy team. Mark engaged with Prescient throughout his tenure with GSK and Covance before joining us in 2013. He is responsible for establishing, solidifying and expanding client relationships by engaging with industry executives and bringing clarity to our solutions.

Vice President

Dr. Aviral Maheshwari

Aviral is an Vice President at Prescient. He completed his MBBS and MS degrees at Jawaharlal Nehru Medical College, India, and his MBA at IESE Business School, Spain. Aviral has developed a strategic understanding of both the clinical and commercial sides of the life sciences industry from working as a physician for eight years and holding strategic consultancy roles at GlaxoSmithKline Biologicals and Grail Research. Since joining Prescient in 2010, Aviral has examined all aspects of the product life cycle for companies developing biologics, biosimilars and generics, OTC medicines, vaccines and medical devices within CVMD, respiratory disease, gastroenterology, immunology, dermatology, neurology and ophthalmology.

Vice President, Head of Software Development

Tarun Ojha

Tarun is spearheading the development of InflexionRx. He obtained his Master’s degree in computer applications from M.B.M Engineering College, and has more than 18 years of experience in product management, enterprise application design and development and entrepreneurship. He has worked with small- to medium-sized technology start-ups and is an expert in product ideation, conceptualization, development from proof of concept to final product, and market releases. At Prescient, Tarun’s role involves leading and delivering a software platform that creates value for our clients and drives efficiencies within our project teams.

Vice President

Jeanne Penn

Jeanne is a Vice President at Prescient. Prior to joining Prescient, she spent more than 25 years providing strategic insight and planning support to the biopharmaceutical industry. Jeanne has held leadership roles at various companies including EMD Serono and Genzyme. She brings a depth of biopharma experience in brand and strategic planning, indication prioritization, competitive intelligence, workshop design and facilitation, and integration of multiple external perspectives to inform decision-making. At Prescient, Jeanne will leverage her expertise in rare diseases, multiple sclerosis, immunology, inflammatory diseases and fertility to grow and develop client relationships and lead client engagements.

Vice President

Dr. Elisavet Primpidou

Elisavet is a Vice Prescient and joined Prescient in 2008. She holds a PhD in molecular immunology and an MSc in medical genetics from Brunel University London, as well as a BSc in biology from the Royal Holloway University of London. As a consultant to the pharmaceutical industry, Elisavet has gained extensive experience in various aspects of drug development and commercialization, strategic marketing and life cycle management, providing critical analysis and recommendations to brand teams supporting new and existing products in oncology, malignant and non-malignant hematology, vaccines, rare diseases and other areas. Elisavet uses her expertise in evidence gathering to identify key unmet needs, gaps in strategy, opportunities for differentiation and potential threats.

Vice President

Dr. Luke Solon

Luke is a Vice President and Head of our European Advisory business based out of our London office. After studying medicine and working as a doctor in the UK for several years, Luke spent the rest of this career in consulting roles at various firms including McKinsey & Company and Strategy&. He has led and delivered projects across most of the pharmaceutical value chain, as well as multiple therapy areas and geographies. Luke brings deep experience in value and access strategy, portfolio strategy, clinical development strategy, medical affairs strategy, commercial due diligence and life cycle management. Luke prides himself on his collaborative working style, both with clients and colleagues. At Prescient, Luke is responsible for growing our European advisory business and helping our clients address their biggest market access hurdles to maximize their brand’s value.

Vice President

Dr. Anthony Starling

Anthony is one of the longest-serving members of our team. He earned his PhD in pharmacology before becoming a postdoctoral researcher at the University of Southampton. From there, he joined the world of healthcare market research, working for the likes of MMR International, IMS Health and NOP World (now GfK). He has consulted across the therapeutic spectrum and throughout the product life cycle but particularly enjoys developing clinical strategies within oncology, infectious disease and cardio-metabolic diseases.

Director

Amrit Bawa

Amrit has been with Prescient since 2011 and specializes in oncology and hematology. He holds a master’s degree in biotechnology from the University of Pennsylvania. He leads client engagements in Europe and the US. His versatile experience in multiple engagement types and expertise enables him to deliver exceptional services to Prescient’s clients.

Director

Katy Chun

Katy is a Director in our Advisory business. Since earning her master’s of bioscience degree from Keck Graduate Institute, she has acquired several years of life science management consulting experience advising clients on brand, commercialization and corporate portfolio strategy engagements. She has focused on late-stage, pre-launch assets across disease areas including oncology, hematology, dermatology and rare diseases. Katy’s focus at Prescient is on driving the growth of the Advisory team by ensuring engagements are of high quality, expanding Prescient Advisory’s presence and supporting team professional development.

Director

Peter Donachie

Peter is one of our Directors and works across our Advisory and Intelligence & Insight business units. After earning a degree in life sciences, he gained a first-class master’s degree in business at Edinburgh Napier University and a postgraduate qualification in health economics at Aberdeen University. Peter has held scientific, development and commercial leadership roles within the CRO, pharmaceutical and biopharmaceutical industries with Charles River Laboratories, Kyowa Kirin and Ablynx NV, respectively. He has been the Global Launch Director for two orphan drug monoclonal antibody launches, both for the treatment of rare diseases. At Prescient, Peter is responsible for leading successful Intelligence & Insight engagements, growing revenue within existing accounts and providing an expert understanding of the evolving EU biopharmaceutical market. In addition, Peter provides advisory expertise in commercial launch strategy, R&D portfolio and project management, pricing and market access, competitive strategy and opportunity assessment across various therapeutic areas including metabolic bone disease, oncology, hematology, pain management and men’s health.

Director

Paula Palacios Fernández

Paula joined our team in 2015 and is a now a Director in our Intelligence & Insight business. She holds an MSc in medical biology from the University of Oviedo, Spain. She began her academic research career at the University of Roehampton London, investigating the mechanism of metastasis in multiple tumors. At Prescient, Paula coordinates a wide range of engagements with our clients within the oncology space, with a particular focus on drug development strategy and competitive pipeline analysis. She uses her deep knowledge and expertise across treatment paradigms and market dynamics in oncology to advise our clients’ strategies in this area.

Director

Anamika Gera

Anamika heads the Talent and Performance Management Function of our India operation. She is an alumna of IIM Raipur and has an MBA in human resource management. She has more than 10 years of experience in the field of human resources and has worked in diverse industries. At Prescient, Anamika is responsible for talent acquisition and talent development, and she continues to play a pivotal role in the growth and development of our India team.

Director

Easha Ghildyal

Easha is a Director in our Intelligence & Insight business. She has a degree in life sciences and an MBA in marketing and strategy from the Indian School of Business. She has more than 12 years of industry experience and a proven track record of turning compelling market insights into differentiated strategies and solutions. She has worked across the business value chain from R&D, new product launch and commercialization to life cycle management of brands in various therapy areas. She has held strategic and marketing roles in various biopharma companies and led the launch of two blockbuster products in oncology. At Prescient, Easha leads global competitive intelligence programs for leading biopharma companies.

Director

Gordon Gochenauer

Gordon is a Director in our Intelligence & Insight business. He earned his MBA in market and strategy from Carnegie Mellon University and his BA in biochemistry from the University of Pennsylvania. He has over 15 years of dedicated oncology experience in market research and competitive intelligence. Before joining Prescient, Gordon led teams working on projects across the development timeline at Kantar Health, AlphaImpactRx (now part of IQVIA) and Psyma . At Prescient, Gordon is responsible for driving our business growth by expanding our presence, ensuring high-quality engagements and supporting team development.

Director

Nadia Gonzalez

Nadia joined the Prescient team as the US Financial Controller and HR Director. After earning her accounting degree, she developed financial expertise through working with high-end retail and luxury brands headquartered in New York City. While working in retail, Nadia was responsible for the financial reporting and oversight of nationally recognized brands with a presence across the country. The technical expertise and business acumen that she has acquired over the past 15 years have proven to be an invaluable asset to our organization.

Director

Dr. Anuj Gupta

Anuj is a Director at Prescient and works within our Intelligence & Insight business. He has a Bachelor’s degree in dental surgery and Master’s degree in business administration. Prior to joining Prescient, Anuj has held leadership roles across several advisory firms, where he helped global pharmaceutical companies launch drugs, define pricing strategies, optimize supply and distribution chains and re-engineer D2C campaigns and patient engagement strategies. He has authored multiple articles in reputed publications and has been featured in industry debates on leading television networks. At Prescient, Anuj leads our client engagements, by leveraging his broad experience and strategic mindset.

Senior Director

Jatin Gupta

Jatin is a Senior Director and has been with Prescient since 2014. He holds a master’s degree in biotechnology from the University of Manchester and he has worked within the pharmaceutical analysis divisions of major organizations such as Bloomberg. At Prescient, Jatin has directed several global projects while working across domains including immunology, oncology, hematology, neurology, nephrology, endocrinology, respiratory disease and biosimilars. He applies his broad experience and strategic mindset to a variety of engagement types ranging from intelligence-driven consultative projects to strategy development support.

Director

Dr. Priya Kar

Priya is a Director in our Intelligence & Insight business. She earned her PhD in molecular biology from the New Jersey Medical School and MBA in pharmaceutical management and marketing from Rutgers Business School. She has over 15 years of healthcare experience, particularly in the realm of commercial and clinical insights and strategy development. Within her previous roles, she has served as a subject matter expert and was a trusted advisor for her clients. Priya has co-authored several peer-reviewed scientific articles and industry-relevant white papers. At Prescient, Priya is responsible for driving growth within our Intelligence & Insight business, managing key business accounts and providing strategic leadership in coaching teams to deliver successful engagements.

Associate Director

Dr. Haroon Khan

Haroon is an Associate Director in our Advisory business based in London. He holds a doctorate in biochemical engineering from University College London, where he also gives guest lectures on the financial assessment and valuation of biotech start-ups. Prior to joining Prescient, Haroon worked in PwC’s M&A Advisory practice, supporting value creation within global pharma and healthcare deals. He joined PwC from PharmaVentures, a corporate advisory firm focused on the life sciences sector, where he worked on a wide range of transactions covering different disease areas and product types. At Prescient, Haroon is focused on driving the growth of our Advisory business while ensuring delivery of high-quality engagements and expansion of the team’s capabilities across corporate strategy synthesis, product valuation and business development.

Director

Emma Leung

Emma is a Director within the InflexionRx team. She has over 10 years of experience having worked in the UK National Health Service and private pharmaceutical companies, delivering technology and organizational transformation, including process design, establishment of centers of excellence, management reporting and analytics across a range of companies, countries and industries. At Prescient, her role drives our InflexionRx strategy, developing frameworks and ways of working to ensure a consistent, quality structure for our clients. She works with both client and internal teams to roll out the platform and embed it within our business and client interactions.

Director

Rob Littlefield

Rob is a Director within the InflexionRx team, and he holds an MSc in biomedical engineering from Columbia University and a BASc in biomedical engineering from Bucknell University. For over 10 years, Rob has led diverse projects in strategy and intelligence for several biopharmaceutical companies in various therapeutic areas, and his analyses have been featured in numerous well-known publications. At Prescient, Rob manages the InflexionRx decision support platform used to organize intelligence, craft strategies and develop deep insights. He heads change management, client adoption and platform implementation, and he further guides software development and expansion of the platform’s footprint with new clients.

Director

Dr. Cameron Mackenzie

Cameron is a Director in our Intelligence & Insight business. He earned his PhD in biophysical chemistry from the University of Glasgow, MSc in chemistry from the University of Strathclyde and MBA from Strathclyde Business School. He has over 15 years of experience in the pharma and biotech industries. He spent his early career working in R&D and manufacturing in established companies, before joining a start-up to lead the development, launch and global sales of a novel product. He then moved to the consulting sector where he worked with established brands and seed-stage companies. Most recently, he led the BD, licensing and IP management functions at a company developing allogeneic CAR-T assets. At Prescient, Cameron is responsible for leading high-quality engagements with new and existing clients and applying his knowledge and experience to answer their strategic business questions.

Global Head of Marketing

Christina Maffei

Christina joined Prescient as our Director of Global Marketing and heads up all marketing and communications functions. After earning a master’s degree in pharmaceutical business, she pursued careers in both non-profit and commercial sectors. Her experience includes leading marketing strategy for global oncology teams, as well as regionally for the Americas and in emerging markets with Kantar’s Health Division. Christina is responsible for elevating the positioning and messaging of the Prescient brand through the development of strategic marketing programs and thought leadership initiatives.

Director

Matt Majer

Matt is a Director within the InflexionRx team, and he holds a BS in computer science from the University of Illinois at Urbana-Champaign. Matt has extensive experience across both commercial and R&D organizations within large pharmaceutical companies in the US and EU. He has led international project and operations teams responsible for the creation and evolution of digital products for both internal and external customers, providing improvements ranging from operational efficiency to patient outcomes. At Prescient, Matt is responsible for driving digital product direction, development and adoption across our rapidly growing customer base.

Senior Director

Dr. Kallal Pramanik

Kallal is one of the longest-serving members of our India-based team. He has master’s and doctoral degrees in biotechnology, as well as a master’s degree in business administration. After holding various academic research posts in oncology, Kallal became a Lead Scientist at Connexios Life Sciences, where the focus of his group was to design in vitro and ex vivo assays reflecting human pathologies in type 2 diabetes mellitus and to test the efficacy of in-house drugs. Since joining Prescient in 2010, Kallal has managed new product and mature product brand planning projects in the areas of neurology, oncology, immunology and diabetes in both regulated and semi-regulated markets.

Director

Dr. Emmanuel Reyes-Cortes

Emmanuel is a Director for the Prescient Intelligence & Insight business. He holds an MD from the University of Cincinnati College of Medicine and an MSc in immunology from the Medical University of South Carolina. He worked at University of Cincinnati Health for a year while conducting clinical and preclinical research focused on liquid tumors and molecular biology. He then co-founded a consulting firm to help integrate the use of technology into the practice of medicine, originally centered on the implementation and optimization of electronic health record systems. After several years growing the business, Emmanuel entered the pharmaceutical sector as a clinical trial manager in hematology/oncology. At Prescient, Emmanuel leverages his clinical and research experience to support clients as they navigate the complexities of bringing new therapies to patients in need.

Senior Director

Dr. Ashima Sharma

Ashima, a physician by training, is a Senior Director at Prescient. Ashima’s career has included positions with medical institutions, insurance companies and consulting firms. At Prescient, which she joined in 2014, she has worked extensively in biosimilars, hematology and rare disease. She leads client engagements related to strategic BD&L decisions, CI, product label design, commercialization planning, life cycle management and financial modeling.

Senior Director

Sugandh Sharna

Sugandh is a Senior Director in our Intelligence & Insight business. She holds an MS in biotechnology and has over 14 years of experience in setting up new businesses and delivering strong commercial performance and growth in the healthcare consulting, research and intelligence sectors. In her previous roles, Sugandh has led multiple engagements with biopharmaceutical and healthcare companies in the domains of commercial strategy, market access, research, and intelligence across various disease segments. At Prescient, Sugandh is responsible for driving growth within our Intelligence & Insight business by developing successful engagements with clients and coaching teams to deliver high-quality insights and impact.

Director

Dr. Reena Telang

Reena is a Director in our Intelligence & Insight business. With more than a decade of clinical and pharmaceutical industry experience, Reena’s expertise spans consulting, medical affairs, clinical development and medical writing across the immunology, oncology, rheumatology and cardiology areas. She practiced as a physician before transitioning to work with various pharmaceutical companies. In addition to her medical degree, she holds a post-graduate certifiate in Quality and Accreditation of Health Care Organizations. At Prescient, Reena leads multi-dimensional engagements for global pharmaceutical organizations to support their business intelligence strategies across various stages of the product life cycle.

Director

Dr. Mladen Tomich

Mladen is one of our Directors and is responsible for leading engagements across different therapeutic areas. He received his PhD in microbiology from the University of Minnesota and completed his postdoctoral research at Columbia University. Before joining Prescient, Mladen oversaw analyst teams and market research portfolios at Decision Resources Group across various therapeutic areas, including rare and infectious diseases. Previously, he worked at Merck & Co. and MedImmune/AstraZeneca, where he led projects focused on the discovery of novel anti-infectives for the treatment and prevention of serious bacterial infections.

Senior Director

Dr. Nick Turner

Nick, a Senior Director, has a PhD in pharmacology from the University of London and conducted postdoctoral research at London’s Royal Postgraduate Medical School. He began his career in the pharmaceutical industry as a senior scientist to lead the pharmacology effort on discovery research projects in airway diseases at Rhône-Poulenc (now Sanofi) and in asthma and type 2 diabetes at SmithKline Beecham (now GSK). He then spent nearly 19 years as a senior equity analyst at Mirabaud Securities and Jefferies, with responsibility for the pharmaceutical and biotechnology industries. At Prescient, Nick supports clients as a subject matter expert in oncology and hematology.

Collaborate with a Proven and Trusted Partner

Our average partnerships with product teams last more than five years. Prescient adapts to you as your needs change – from molecule to product, product to brand, and brand to the realization of your commercial goals.

We believe that the respect and trust of our clients must be continuously earned. We strive to achieve this by collectively challenging and supporting each other to be the best we can and by individually taking ownership, being accountable and making a difference.

Group 2 (2)

Vision

Our vision is to be the biopharma strategy partner most respected for its people, expertise and impact.

Mission

Our mission is to help biopharmaceutical companies develop, launch and market medicines that expand treatment options, optimize patient outcomes and deliver high levels of return.

Values

We believe that the respect and trust of our clients must be continuously earned. We strive to achieve this by collectively challenging and supporting each other to be the best we can and by individually taking ownership, being accountable and making a difference.

Scroll to Top